MAPT and Alzheimer disease: In previous studies, plasma p‐tau217 consistently demonstrated high accuracy across various platforms and strong correlations with AD markers such as traditional CSF biomarkers,40 amyloid PET findings,41 tau PET findings,42 and neuropathology.43